PredxBio (formerly SpIntellx) announces that it will attend the 2023 Annual Meeting of American Association for Cancer Research in Orlando, April 15-19, Booth #974 and Poster #5445 to present their explainable AI-powered unbiased spatial analytics platform, that seamlessly integrates multimodal data to unravel the hidden circuitries of the tumor microenvironment and reveal the complex network biology of the cancer.
PITTSBURGH, April 17, 2023 /PRNewswire-PRWeb/ -- PredxBio, formerly known as SpIntellx, is set to showcase its innovative platform at the 2023 Annual Meeting of the American Association for Cancer Research in Orlando, Florida from April 15-19. The company will present its explainable AI-powered unbiased spatial analytics platform that integrates multimodal data to reveal the hidden circuitries of the tumor microenvironment and expose the complex network biology of cancer. The PredxBio platform has been designed to address the challenges of managing cancer patients with immunotherapy, as it only works about 20% of the time, and commercialized diagnostic tests do not provide the tools to make better decisions. By analyzing complex signals from multiple spatial omics technologies, including spatial proteomics, spatial transcriptomics, and brightfield pathology images, PredxBio aims to improve prediction accuracies and drive personalized therapeutic options not only for PD1/PDL1 inhibitor-based therapies but also for novel bispecific/multi-specific antibody therapeutics, and cutting edge chimeric antigen receptor (CAR)-T cell therapies.
At the AACR Annual Meeting, PredxBio will showcase its latest innovations in unbiased spatial analytics and explainable AI, demonstrating how its platform can extract valuable information from patient disease pathology samples imaged with any technology including brightfield pathology, spatial proteomics and/or spatial transcriptomics. PredxBio will be presenting a scientific poster (#5445) showcasing its work on cell segmentation-free analysis of multiplexed images with unbiased spatial analytics and explainable AI for predicting disease outcomes.
The first step in the current approaches for extracting high-value knowledge from multiplexed datasets is to segment cells accurately. Despite decades of research, this step remains elusive due to imaging artifacts leading to low-quality cell segmentation. Those artifacts may lead to incorrect cell phenotypes, incomplete cell phenotype atlases, and missing rare cell, fusion cell and/or transition cell types. To address these issues, PredxBio will showcase a segmentation-free approach on a challenging, low-resolution hyperplexed imaging mass cytometry dataset of triple negative breast cancer. This approach discovers functional collections of neighboring pixels highly predictive of disease progression and leads to tumor promoting and tumor restraining microdomains and microdomain-specific network biology predictive of disease outcomes.
"We are unraveling the dynamics of the tumor microenvironment by capturing inter- and intra-cellular communications and their distinct spatial configurations, named microdomains. We believe, deriving spatial network biology within each microdomain is key to understanding tumor initiation, progression, and response to therapy thus enabling better patient outcomes" said B. Dusty Majumdar, PhD, CEO of PredxBio.
The PredxBio platform is designed to improve prediction accuracies and drive personalized therapeutic options for selecting optimal therapeutics based on insights into spatial tumor biology of individual patients and their potential outcomes. With the launch of the PredxBio brand, the company is positioned in spatial biology space with the truly unique capability of unravelling the hidden biological circuitries of cancer to predict patient outcomes with 90%+ accuracy.
"The AACR Annual Meeting is an excellent opportunity for PredxBio to showcase our technology and its potential to revolutionize the field of cancer research," added S. Chakra Chennubhotla, PhD, Chief of AI and COO of PredxBio. "We are excited to share our latest innovations in unbiased spatial analytics and explainable AI and demonstrate how our platform can be used to extract valuable information from patient disease pathology samples imaged with any technology."
PredxBio will be presenting at the AACR Annual Meeting from April 15-19, 2023, at booth #974. Attendees are encouraged to stop by to see demonstrations of their software platform and to learn more about how PredxBio is working to advance the field of cancer research.
About PredxBio
PredxBio is a Pittsburgh, PA-based scaling-stage company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and accelerate innovation in precision pathology and spatial biology. PredxBio's solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio's solutions to assess treatment response in immunotherapy.
Media Contact
S. Chakra Chennubhotla, PhD, PredxBio, Inc., 1 4122123115, [email protected]
SOURCE PredxBio, Inc.
Share this article